{
  "ticker": "LLY",
  "target_date": "2025-01-09",
  "actual_date": "2025-01-08",
  "collected_at": "2025-12-08T11:15:28.597312",
  "price": {
    "open": 768.1,
    "high": 786.69,
    "low": 764.96,
    "close": 781.3916625976562,
    "volume": 3478400,
    "change_1d_pct": 1.8,
    "change_7d_pct": 0.52,
    "change_30d_pct": 5.24
  },
  "technicals": {
    "rsi_14": 53.23,
    "sma_20": 774.99,
    "sma_50": 786.91,
    "macd": -6.184,
    "macd_signal": -7.414,
    "macd_histogram": 1.23,
    "bb_upper": 798.91,
    "bb_lower": 751.08,
    "price_vs_sma20_pct": 0.83,
    "price_vs_sma50_pct": -0.7,
    "volume_ratio": 1.09
  },
  "fundamentals": {
    "market_cap": 890342932480,
    "pe_ratio": 48.66144,
    "forward_pe": 43.829655,
    "price_to_book": 37.393826,
    "price_to_sales": 14.983944,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.68,
    "pct_from_52w_low": 59.22
  },
  "macro": {
    "spy": {
      "price": 584.37,
      "change_1d_pct": 0.15,
      "change_7d_pct": 0.22
    },
    "vix": {
      "level": 17.7,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.69
    },
    "dollar_index": {
      "level": 109.18
    },
    "gold": {
      "price": 2683.8
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?",
      "source": "Yahoo",
      "datetime": 1736456577,
      "summary": "We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy for 2025. Both conservative and risk-tolerant investors favor blue chip stocks due to the",
      "url": "https://finnhub.io/api/news?id=135d0646fdf6e244865001c12830d80ddf01fc1a8fd664e2b98fab6b80f4a5f8"
    },
    {
      "headline": "Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea",
      "source": "Yahoo",
      "datetime": 1736455008,
      "summary": "Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.",
      "url": "https://finnhub.io/api/news?id=e0540c28935ef448fe82ed6d8013a335a50bf55ecae41b1c54efb34a15aacb00"
    },
    {
      "headline": "Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge.",
      "source": "Yahoo",
      "datetime": 1736441580,
      "summary": "The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that afflicts many severely obese people.",
      "url": "https://finnhub.io/api/news?id=8556098423a95c5c068c6071fa91d81edd76c899e34117fb31277b8b8448e019"
    },
    {
      "headline": "NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy",
      "source": "Yahoo",
      "datetime": 1736435100,
      "summary": "Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.",
      "url": "https://finnhub.io/api/news?id=efb24f52bedda28142dcff3dd813536d138d2cfe0188ffd495a0a0c8a290a62e"
    },
    {
      "headline": "LLY Falls Around 14% in 3 Months: How to Play the Stock",
      "source": "Yahoo",
      "datetime": 1736428680,
      "summary": "Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.",
      "url": "https://finnhub.io/api/news?id=cf082d330fa178aa5e296a5b10f7f05eae09f0c58b3df83a2d5049aa39278a23"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}